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A B S T R A C T
This study investigated the mechanisms involved in reduced susceptibility to amoxycillin–clavulanic
acid and the prevalence of enzymes compatible with inhibitor-resistant TEM (IRT) b-lactamases
produced by Escherichia coli isolates from patients in north-eastern Spain. The resistance mechanisms of
158 strains showing resistance or intermediate resistance to amoxycillin–clavulanic acid among 1122
ampicillin-resistant clinical isolates of E. coli were assessed on the basis of their b-lactam resistance
phenotypes. b-Lactamases produced by strains showing resistant phenotypes suggestive of inhibitor-
resistant penicillinase production were characterised by their isoelectric point. Specific activity and the
concentration of clavulanic acid required to inhibit b-lactamase activity by 50% (IC50) were determined
in strains harbouring enzymes that focused at pI 5.2 or 5.4 in order to achieve presumptive identification
of IRT b-lactamases. Resistance phenotypes were consistent with overproduction of TEM-1, TEM-2 or
SHV-1 b-lactamases in 56 strains, with AmpC cephalosporinase hyperproduction in 46 strains, and with
production of inhibitor-resistant penicillinases in 49 strains. Of the latter isolates, 17 produced
moderately high or high levels of enzymes co-focusing with TEM-1, 17 produced enzymes co-focusing
with OXA-1 (n ¼ 12) or with PSE-1 (n ¼ 5), either alone or in association with TEM-1, while only 15
produced enzymes with a phenotype characteristic of IRT b-lactamases. It was concluded that resistance
to amoxycillin–clavulanic acid in E. coli isolates from this area was mainly associated with presumptive
overproduction of TEM-1, TEM-2 or SHV-1 b-lactamases (46%) or of AmpC cephalosporinase (29%),
while the occurrence of enzymes categorised as IRT b-lactamases was unusual (9.5%).
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I N T R O D U C T I O N
Clavulanic acid, as well as the penicillanic acid
sulphones sulbactam and tazobactam, functions
as an irreversible suicide inhibitor of Ambler class
A b-lactamases. Clavulanic acid is used to protect
labile b-lactam antibiotics from hydrolysis indu-
ced by bacterial b-lactamases. Hence, the antibac-
terial spectrum of inhibition of ticarcillin and
amoxycillin is substantially enhanced when these
drugs are administered as clavulanate-containing
combinations [1]. Some of the b-lactamases effect-
ively inhibited by clavulanic acid are TEM-1,
TEM-2 and SHV-1, the most common b-lactamas-
es in Escherichia coli [2]. Resistance to amoxycillin–
clavulanic acid in E. coli, reported as early as 1987
[3], may be mediated by mechanisms such as:
(1) hyperproduction of the plasmid-encoded
b-lactamases TEM-1, TEM-2 or SHV-1 [4,5]; (2)
overproduction of the constitutive AmpC ceph-
alosporinase [6]; (3) production of OXA enzymes
(penicillinases poorly inhibited by b-lactamase
inhibitors) [7]; (4) a deficiency in the OmpF
and ⁄ or OmpC porins [8]; and (5) production
of inhibitor-resistant TEM (IRT) b-lactamases
[9,10].
IRT b-lactamases, first described in France in
1992, are plasmid-encoded enzymes derived from
TEM-1 or TEM-2. Substitutions of one or more
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amino-acid residues at positions 69, 130, 244, 275
and 276 give rise to structural changes in the
b-lactamase that affect its affinity for inhibitors,
but produce only slight modifications in the
isoelectric point (pI) and in activity against other
b-lactam compounds. Substitutions in other posi-
tions, such as 127, 165, 182 and 261, have been
found in IRT b-lactamases, but do not seem to be
involved in the IRT phenotype. IRT-producing
strains are resistant to amoxycillin, ticarcillin,
amoxycillin–clavulanic acid and, generally, piper-
acillin and ticarcillin–clavulanic acid, but remain
susceptible to narrow-spectrum cephalosporins,
cephamycins, extended-spectrum cephalospo-
rins, and, in most cases, piperacillin–tazobactam
[11,12].
The emergence of IRT b-lactamases is probably
related to the selective evolutionary pressure
posed by increasing use of inhibitor-containing
combinations in clinical practice, which has led to
the selection of different mutants of TEM-1 and
TEM-2 that confer resistance to inhibitors [13].
Furthermore, inhibitor-resistant b-lactamases
derived from SHV-5 and OXY-2 have been des-
cribed recently in E. coli and Klebsiella oxytoca,
respectively [14,15]. Unlike TEM-derived exten-
ded-spectrum b-lactamases, IRT b-lactamases
occur mainly in community-acquired isolates of
E. coli, but have also been detected in rare clinical
isolates of Proteus mirabilis, Klebsiella pneumoniae
and Shigella sonnei [16–18].
There have been a few reports documenting
the presence of different IRT b-lactamases in
isolates from France, Spain, the UK and Portugal
[6,9,10,16–22], but there is a dearth of informa-
tion concerning their geographical distribution.
This could result from standard laboratory
susceptibility tests being insufficiently reliable
to identify this type of enzyme, since definitive
characterisation can only be accomplished with
relatively sophisticated methodologies, such as
determination of the pI, enzyme kinetic para-
meters, the concentrations of inhibitors required
to inhibit 50% of the b-lactamase activity
(IC50), and, on occasion, molecular techniques
[21,23].
The present study was undertaken to investi-
gate the mechanisms involved in reduced sus-
ceptibility to amoxycillin–clavulanic acid in E. coli
isolates from a health region in north-eastern
Spain, and to assess the prevalence of IRT
b-lactamase-producing strains.
M A T E R I A L S A N D M E T H O D S
Strains
Non-duplicate ampicillin-resistant isolates of E. coli (n ¼ 1122)
were consecutively recovered from patients with community-
acquired and nosocomial infections in January 1998 to April
1999 from the microbiology laboratory of the Hospital de
Tortosa Verge de la Cinta. Isolates were from clinical speci-
mens (mainly urine, blood and abscess swabs) from patients
attending either the referral hospital or the 33 associated
primary healthcare centres of the health region of Tortosa
(southern Catalonia, north-eastern Spain). All samples were
analysed in the same centralised laboratory of the referral
hospital.
Susceptibility testing
MICs of ampicillin, ticarcillin, piperacillin, cefazolin and
cefoxitin were determined by the commercial microdilution
PASCO susceptibility testing system (Difco, Detroit, MI, USA).
MICs of amoxycillin–clavulanic acid, ticarcillin–clavulanic acid
and piperacillin–tazobactam were obtained by the Etest
method (AB Biodisk, Solna, Sweden). Amoxycillin–clavulanic
acid was tested at a 2 : 1 fixed ratio, while ticarcillin–clavulanic
acid and piperacillin–tazobactam were assayed at fixed inhib-
itor concentrations of 2 and 4 mg ⁄L, respectively. National
Committee for Clinical Laboratory Standards criteria for
susceptibility and resistance [24] were applied, and the E. coli
TEM-1 producer strain (ATCC 35218) was used as a reference.
Phenotype definition
Strains that were intermediate (MIC 16 + 8 mg ⁄L) or resistant
(MIC ‡ 32 + 16 mg ⁄L) to amoxycillin–clavulanic acid were
classified into four different groups on the basis of their
b-lactam resistance phenotypes: (1) strains displaying pheno-
type HP (resistant to ticarcillin and piperacillin, resistant
or intermediate to amoxycillin–clavulanic acid, ticarcillin–
clavulanic acid and cefazolin, and sensitive to cefoxitin
that might be TEM-1, TEM-2 or SHV-1 hyperproducers;
(2) strains displaying phenotype C (resistant or intermediate
to amoxycillin–clavulanic acid, cefazolin and cefoxitin, and
intermediate or sensitive to ticarcillin, ticarcillin–clavulanic
acid, piperacillin and piperacillin–tazobactam) that might
be AmpC cephalosporinase hyperproducers; (3) strains
displaying phenotype P + C (resistant to ticarcillin, resistant
or intermediate to amoxycillin–clavulanic acid, ticarcillin–
clavulanic acid, piperacillin, cefazolin and cefoxitin, and
intermediate or sensitive to piperacillin–tazobactam) that
might be AmpC cephalosporinase hyperproducers with a
plasmid-encoded penicillinase; and (4) strains displaying
phenotype IR (resistant to ticarcillin, resistant or intermediate
to amoxycillin–clavulanic acid and piperacillin, and sensitive
to cefazolin and cefoxitin) that might be IRT b-lactamase
producers [25].
b-Lactamase assays
Crude enzyme preparations for b-lactamase assays were
obtained from overnight cultures after centrifugation (15 530 g
for 30 min at 4 C) of sonicated cells (three 1-min high-
frequency bursts on ice at 160 W). b-Lactamases produced by
strains displaying a phenotype consistent with production of
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inhibitor-resistant penicillinases were characterised by their
pI. Isoelectric focusing was performed with crude sonicated
bacterial extracts applied to polyacrylamide gels (pH gradient
3.5–9.5) in an LKB-Multiphor II isoelectric focusing tank
(Pharmacia, Uppsala, Sweden), as described previously [5].
b-Lactamases were visualised after staining with nitrocephin
(500 mg ⁄L). Strains known to produce TEM-1 (pI 5.4), TEM-2
(pI 5.6), SHV-1 (pI 7.6), OXA-1 (pI 7.4), OXA-2 (pI 7.7) or
PSE-1 (pI 5.7) were used as standards and were run in parallel
with the test samples.
b-Lactamase specific activity, and the concentrations of
clavulanic acid required to inhibit 50% of the b-lactamase
activity (IC50), were determined for strains harbouring
b-lactamases that focused at pI 5.2 or 5.4. The specific activity
(U ⁄mg protein) was measured by spectrophotometry at
482 nm with nitrocephin as a substrate at a final concentration
of 20 lM. Total protein concentration in crude enzyme prep-
arations was determined by the indocyanin method (QCA,
Amposta, Spain). One unit of b-lactamase activity was defined
as the amount of enzyme that hydrolysed 1 nmol of nitroce-
phin ⁄min in sodium phosphate buffer (pH 7.2). Inhibition
studies were performed by measuring the residual b-lactamase
activity of enzyme preparations that had been preincubated
with clavulanic acid (0.1–100 lM) for 15 min at room tempera-
ture. A preparation of the TEM-1 enzyme, produced at a basal
level from the ATCC 35218 strain, was used as a reference.
Enzymes focusing at pI 5.2 or 5.4 with an IC50 for
clavulanic acid of > 1 lM were considered to be presumptive
IRT b-lactamases, while those focusing at pI 5.4 with an IC50
for clavulanic acid of c. 0.1 lM were considered to be probable
TEM-1 enzymes [10,12]. Hyperproduction of TEM-1 b-lacta-
mase was defined as a specific activity of > 58 U ⁄mg, since,
in a previous study, this was the value representing the
75th percentile derived from 192 TEM-1-producing clinical
isolates of E. coli that were amoxycillin-clavulanic acid
susceptible [5].
R E S U L T S
In-vitro susceptibility to amoxycillin–clavulanic
acid and strain classification according to
b-lactam resistance patterns
Of the 1122 ampicillin-resistant strains investi-
gated, 964 (86%) were susceptible to amoxycillin–
clavulanic acid, 127 (11%) were intermediate, and
31 (3%) were resistant. Fig. 1 summarises the
results obtained when the 158 amoxycillin–
clavulanic acid-intermediate or -resistant strains
were classified on the basis of their b-lactam
resistance phenotype. The resistance patterns
most frequently encountered among intermediate
strains were those consistent with overproduction
of TEM-1, TEM-2 or SHV-1 b- lactamases (phe-
notype HP; 42%), or with production of inhib-
itor-resistant penicillinases (phenotype IR; 29%).
Most amoxycillin–clavulanic acid-resistant
isolates (39%) showed a resistance phenotype
suggestive of inhibitor-resistant penicillinase pro-
duction (phenotype IR). Phenotype C, which
could correspond to hyperproduction of AmpC
cephalosporinase, was the second most common
resistance pattern among these strains (32%).
Seven strains (four intermediate and three resist-
ant to amoxycillin–clavulanic acid) showed resist-
ance patterns that did not conform to any of the
phenotypes defined above, since they were sus-
ceptible to cefazolin and resistant to cefoxitin, as
well as to cefuroxime.
Characterisation of the b-lactamases produced
by isolates showing resistance phenotype IR
Characterisation of the b-lactamases produced by
the 37 amoxycillin–clavulanic acid-intermediate
strains that showed a resistance pattern suggestive
of inhibitor-resistant penicillinases (phenotype IR)
(Fig. 2a) revealed that 17 had an enzyme that
focused at pI 5.4, six had an enzyme that focused at
pI 5.2, and 14 produced enzymes that co-focused
with OXA-1 or PSE-1, either alone or in combina-
tion with an enzyme co-focusing with TEM-1.
Fourteen of the 17 strains harbouring a single
enzyme that focused at pI 5.4 were considered to
be probable TEM-1 hyperproducers, because their
specific activities were in the range 58–320 U ⁄mg
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Fig. 1. Percentage of amoxycillin–clavulanic acid (A ⁄C)-
intermediate (MIC 16 + 8 mg ⁄L) or -resistant (MIC ‡
32 + 16 mg ⁄L) strains showing each of the different resist-
ance phenotypes against b-lactams: phenotype HP, con-
sistent with hyperproduction of TEM-1, TEM-2 or SHV-1
b-lactamases; phenotype C, consistent with AmpC ceph-
alosporinase hyperproduction; phenotype P + C, consis-
tent with AmpC cephalosporinase hyperproduction plus
plasmid-encoded penicillinase production; phenotype IR,
consistent with production of inhibitor-resistant penicill-
inase.
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three remaining strains with pI 5.4 enzymes, and
the six isolates with an enzyme focusing at pI 5.2,
were considered to be probable IRT b-lactamase
producers, since the clavulanic acid IC50 was
> 10 lM. The specific activity of these isolates was
6–64 U ⁄mg. The mean IC50 and specific activity
measured in the reference strain (ATCC 35218)
were 0.1 lM and 32 U ⁄mg, respectively.
With regard to the b-lactamases identified in
the 12 amoxycillin–clavulanic acid-resistant strains
showing resistance phenotype IR (Fig. 2b), an
enzyme focused at pI 5.4 in five strains, an
enzyme focused at pI 5.2 in four strains, and
an enzyme co-focused with OXA-1 in three
strains. Of the pI 5.4 b-lactamase producers, three
were probable TEM-1 hyperproducers (specific
activity of 80–640 U ⁄mg and clavulanic acid IC50
of c. 0.1 lM). The two remaining enzymes with
pI 5.4 and the four enzymes with pI 5.2 were
typical of IRT b-lactamases (specific activity of
12–75 U ⁄mg and clavulanic acid IC50 of > 10 lM).
Overall, the presence of b-lactamases with
phenotypic features analogous to those of IRT
b-lactamases was demonstrated in nine (24%) of
the 37 amoxycillin–clavulanic acid-intermediate
strains and in six (50%) of the 12 amoxycillin–
clavulanic acid-resistant strains with a resistance
phenotype consistent with the production of
inhibitor-resistant penicillinases. This indicated
an overall positive predictive value of resistance
phenotype IR of 31%.
The in-vitro susceptibility to ticarcillin–clavul-
anic acid and piperacillin–tazobactam of strains
with resistance phenotype IR varied depending
on the type of b-lactamases produced (Table 1),
with piperacillin–tazobactam being more active
than ticarcillin–clavulanic acid, irrespective of the
type of enzyme. Four of the 15 strains presumably
producing IRT b-lactamases were susceptible to
ticarcillin–clavulanic acid, and 13 were suscept-
ible to piperacillin–tazobactam.
Prevalence of the different resistance
mechanisms
Resistance patterns and phenotypic b-lactamase
characterisation indicated that presumptive
hyperproduction of TEM-1, TEM-2 or SHV-1
plasmid-encoded b-lactamases (46%) and of
AmpC cephalosporinase (29%) were the most
frequent mechanisms involved in reduced sus-
ceptibility to amoxycillin–clavulanic acid in the E.
coli strains investigated (Fig. 3). The estimated
prevalence of IRT-like b-lactamase producers over
the period covered by the study was 9.5%
(± 4.5%) among strains with reduced susceptibil-
ity to amoxycillin–clavulanic acid, and 0.8%
(± 0.5%) among the overall E. coli isolates.
D I S C U S S I O N
Reported frequencies of resistance to amoxycillin–
clavulanic acid in E. coli have varied considerably,
between the 5% observed in the UK in 1990–94 [6]
and the 40% found by Henquell et al. [26] in
nosocomial urinary strains collected in France in
1993. Such discrepancies may have resulted not
only from geographical and temporal differences,
β-Lactamases produced by  
amoxycillin/clavulanate-
resistant strains with 
phenotype IR
n=12
pI 5.4 ; n=5
pI 5.2 presumptive IRT β-lactamases; n=4
Cofocusing with OXA-1; n=2
Cofocusing with TEM-1+ OXA-1; n=1
Presumptive TEM-1 (overproduced); n=3
Presumptive IRT β-lactamases; n=2 
β-Lactamases produced by  
amoxycillin/clavulanate-
intermediate strains with 
phenotype IR
n=37
pI 5.4 ; n=17
Cofocusing with OXA-1; n =5
 Cofocusing with TEM-1+ OXA-1; n=4
Cofocusing with PSE-1; n=4
Cofocusing with TEM-1 + PSE-1; n=1
Presumptive TEM-1 (overproduced); n=14
Presumptive IRT β-lactamases; n=3
pI 5.2 presumptive IRT β-lactamases;  n=6
(a)
(b)
Fig. 2. (a) Characteristics of b-lactamases produced by
amoxycillin–clavulanic acid-intermediate strains (MIC
16 + 8 mg ⁄L) showing a resistance pattern consistent with
inhibitor-resistant penicillinase production (phenotype IR).
(b) Characteristics of b-lactamases produced by amoxycil-
lin–clavulanic acid-resistant strains (MIC ‡ 32 + 16 mg ⁄L)
showing a resistance pattern consistent with inhibitor-
resistant penicillinase production (phenotype IR).
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but also from differences in laboratory methodo-
logy and in antimicrobial susceptibility break-
point guidelines [5,6,19,26–28]. Resistance to
amoxycillin–clavulanic acid in E. coli is relatively
infrequent in the Tortosa area, and has remained
steady over recent years, despite the widespread
use of this therapeutic combination. For exam-
ple, the resistance to amoxycillin–clavulanic acid
observed in the present study (8.5% of E. coli
isolates and 14% of ampicillin-resistant strains)
was similar to that obtained in a survey conduc-
ted in 1995–96 (7% and 15%, respectively) [5].
Similar findings were reported by Stapleton et al.
[6] in 1990–94 and by Leflon-Guibout et al. [28] in
1996–98.
The results of the present study indicated that
the presumed overproduction of TEM-1, TEM-2
or SHV-1 plasmid-encoded b-lactamases, which
was present in 46% of strains with reduced
susceptibility to amoxycillin–clavulanic acid,
was the main mechanism responsible for resist-
ance to amoxycillin–clavulanic acid in E. coli.
Presumed hyperproduction of AmpC cephalo-
sporinase was the predominant mechanism of
resistance among amoxycillin–clavulanic acid-
resistant strains (42%), and the second most
common among intermediate isolates (26%).
These data are in agreement with those reported
by Leflon-Guibout et al. [28], although other
investigators have observed a larger proportion
of TEM-1 overproducers, as well as AmpC
cephalosporinase hyperproducers, in the range
of 4–20% [6,19,26,29].
Enzymes co-focusing with the oxacillinase
OXA-1, known to be more poorly inhibited by
clavulanic acid than class A penicillinases, and
those co-focusing with the carbenicillinase PSE-1
accounted for 8% and 3%, respectively, of the
b-lactamases identified in the present study
among strains with reduced susceptibility to
amoxycillin–clavulanic acid. Between 5% and
15% of the isolates in previous studies produced
OXA-1 enzymes, while PSE-1 was not detec-
ted [6,19,26,28]. However, the presence of this
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Fig. 3. Inferred prevalence of the different mechanisms of
resistance among the 158 E. coli isolates with reduced
susceptibility to amoxycillin–clavulanic acid (A ⁄C), based
on resistance patterns and phenotypic b-lactamase charac-
terisation combined: PEN-H, overproduction of TEM-1,
TEM-2 or SHV-1 b-lactamases; IRT, production of
presumptive IRT b-lactamases; OXA-1, production of a
b-lactamase co-focusing with OXA-1 ± production of a
b-lactamase co-focusing with TEM-1; PSE-1, production of
a b-lactamase co-focusing with PSE-1 ± production of a
b-lactamase co-focusing with TEM-1; CASE-H, hyperpro-
duction of AmpC cephalosporinase ± production of plas-
mid-encoded penicillinase; UM, unknown mechanism.
Table 1. Correlation between the
in-vitro susceptibility to ticarcillin–
clavulanate and piperacillin–
tazobactam of strains showing a
resistance pattern consistent with
the production of inhibitor-resistant
penicillinases (phenotype IR), and




(MIC £ 16 + 2 mg ⁄L)
Piperacillin–tazobactam
(MIC £ 16 + 4 mg ⁄L)
Presumptive TEM-1 overproductiona
(n ¼ 17) 0 13 (76%)
Presumptive IRT b-lactamaseb
(n ¼ 15) 4 (27%) 13 (87%)
Co-focusing with OXA-1
(n ¼ 7) 2 (29%) 5 (71%)
Co-focusing with OXA-1 + TEM-1
(n ¼ 5) 0 4 (80%)
Co-focusing with PSE-1
(n ¼ 4) 0 4 (100%)
Co-focusing with PSE-1 + TEM-1
(n ¼ 1) 0 1 (100%)
ab-Lactamases focusing at pI 5.4, with specific activity > 58 U ⁄mg and clavulanic acid IC50 c. 0.1 lM.
bb-Lactamases focusing at pI 5.2 or 5.4 and with clavulanic acid IC50 > 1 lM.
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ously, and reduced susceptibility to amoxycillin–
clavulanic acid and ticarcillin–clavulanic acid of
the PSE-1-producing strains may result from the
high rate of hydrolysis of the b-lactam rather than
from clavulanate resistance of this enzyme [30].
Finally, 7% of amoxycillin–clavulanic acid-
intermediate strains and 19% of the resistant
strains harboured enzymes focusing at pI 5.2 or
5.4 that were identified as IRT b-lactamases on the
basis of their low specific activity and high IC50 of
clavulanic acid, whereas no strain was identified
that produced an IRT b-lactamase focusing at
pI 5.6. Full characterisation of these enzymes
would require molecular techniques such as gene
amplification and sequencing; nevertheless, their
phenotypic responses strongly suggest that they
are IRT b-lactamases. The possibility cannot be
ruled out that the frequency of this resistance
mechanism was underestimated in the current
study, since the b-lactamases from strains that
were resistant to cefazolin or cefoxitin have not
been characterised. Chaiby et al. [23] demonstrated
that the resistance phenotypes of isolates simulta-
neously producing IRT b-lactamases and high
levels of AmpC cephalosporinase were atypical
and identical to those shown by hyperproducers of
AmpC cephalosporinase plus TEM-1.
The contribution of IRT enzymes to amoxycil-
lin–clavulanic acid resistance in E. coli appears to
be quite different in isolates from different
countries. For example, only 4% of resistant
isolates in a UK survey conducted in 1990–94
produced IRT b-lactamases [6], while the repor-
ted frequency of resistance to amoxycillin–
clavulanic acid associated with the production
of IRT enzymes was c. 30% in France [19,26,28],
and reached 45% in urinary isolates from
patients attending outpatient clinics [26]. In
Spain, Mun˜oz Bellido et al. [29] analysed the
resistance pattern of 108 E. coli strains (amoxy-
cillin–clavulanic acid intermediate and resistant)
isolated from urine, and observed that none had
the characteristic phenotype of IRT b-lactamase
producers.
From the current results, as well as those of
other investigations [21,31], it can be concluded
that the resistance phenotype does not differen-
tiate between isolates that produce IRT enzymes
and those producing oxacillinases or moder-
ately high levels of TEM-1. To improve specific-
ity in the detection of IRT b-lactamases, the
measurement of disk zone inhibition diameters
with cefepime, ceftazidime and mecillinam has
been suggested [32]. Keeping in mind the low
positive predictive value of the resistance pheno-
type for the detection of IRT enzymes observed in
the present study, susceptibility testing of these
antibiotics could be a useful tool to routinely
screen for IRT-producing strains.
In contrast to other studies [6,26], IRT-like
b-lactamases were detected not only among iso-
lates that were clearly resistant to amoxycillin–
clavulanic acid, but also among those that were
intermediate–resistant (MIC 16 + 8 mg ⁄L). This
was the case for nine of the 15 strains (60%) that
produced enzymes designated as IRT b-lactamas-
es. Nevertheless, many of the amoxycillin–clavul-
anic acid-intermediate isolates would probably
have been considered resistant if a fixed inhibitor
concentration of 2 mg ⁄L had been employed [33]
instead of a 2 : 1 ratio. Indeed, Wu et al. [34]
identified an IRT-1 enzyme from an E. coli strain
whose MIC for amoxycillin–clavulanic acid was
16 + 8 mg ⁄L.
Although the IRT phenotype has generally been
characterised [26,31] as resistance or intermediate
resistance to amoxycillin–clavulanic acid and
ticarcillin–clavulanic acid, four pI 5.2 IRT-like
producers that were susceptible to ticarcillin–
clavulanic acid were noted. A possible explan-
ation for this finding could be that IRT enzymes,
notably the pI 5.2 derivatives IRT-2 and IRT-15,
have lower catalytic efficiencies against ticarcillin,
narrow-spectrum cephalosporins and, to a lesser
extent, the rest of the b-lactams than their TEM
ancestors [9,35]. Hence, IRT-producing strains
would show lower resistance to ticarcillin than to
amoxycillin, and, consequently, the MIC of ticar-
cillin–clavulanic acid would be generally lower
than the MIC of amoxycillin–clavulanic acid.
The prevalence of IRT b-lactamases among
E. coli isolates from this geographical area appears
to be very low at the present time (0.8% of total
E. coli isolates and 9.5% of those with reduced
susceptibility to amoxycillin–clavulanic acid).
Reported frequencies in the UK and France were
0.2% [6] and 3–5% [19,26], respectively. Produc-
tion of IRT b-lactamases is an emerging, but
theoretically inefficient, mechanism of resistance.
This is because it protects bacteria specifically
against the action of inhibitors, but not against the
effects of other b-lactams. Definitive identification
of IRT b-lactamases is cumbersome and cannot be
achieved by routine susceptibility tests [12]. As
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such, strains of E. coli and other Enterobacteriaceae
that produce IRT b-lactamases are probably much
more common than is currently thought. The
influence of the widespread use of b-lactamase
inhibitors in combination with b-lactams on the
selection and diffusion of IRT enzymes is a matter
of increasing concern. Knowledge of the repercus-
sions of the dissemination of this resistance mech-
anism on the treatment of infections caused by
Gram-negative bacteria requires reliable data on
its prevalence in different geographical areas and
the consequent clinical outcome of patients.
In conclusion, amoxycillin–clavulanic acid resis-
tance in E. coli isolated in this geographical area
seems to be mainly associated with presump-
tive overproduction of TEM-1, TEM-2 or SHV-1
b-lactamases, or of AmpC cephalosporinase.
Based on an analysis of resistance phenotypes,
pI values, and poor inhibition of enzymatic
activity by clavulanic acid, IRT b-lactamases
remain unusual in this region of Spain, although
molecular methods should be applied to deter-
mine the actual prevalence.
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